Cetera Investment Advisers
HEPA

Cetera Investment Advisers’s Hepion Pharmaceuticals HEPA Stock Holding History

Cetera Investment Advisers’s Portfolio HEPA Stock Details HEPA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-20
Closed -$15.3K – 2253
2023
Q1 		$15.3K Sell
20
-10
-33% -$7.39K ﹤0.01% 2128
2022
Q4 		$8.93K Buy
30
+19
+173% +$8.03K ﹤0.01% 2081
2022
Q3 		$6K Buy
+11
New +$6.72K ﹤0.01% 1666

Other funds holding HEPA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Cetera Investment Advisers's HEPA Position: Q2 2023 in Review

Cetera Investment Advisers sold out of Hepion Pharmaceuticals (HEPA) in Q2 2023, closing a stake of 20 shares — an estimated $15.3K sold.

Cetera Investment Advisers first reported a position in HEPA in Q3 2022 and held it in 3 quarters. The position peaked at $15.3K in Q1 2023. 16 funds tracked by Wall St. Rank hold HEPA as of Q2 2023.

  • Cetera Investment Advisers reported no remaining Hepion Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Cetera Investment Advisers sold 20 Hepion Pharmaceuticals shares in Q2 2023, an estimated $15.3K.
  • Cetera Investment Advisers first reported a position in Hepion Pharmaceuticals in Q3 2022 and held it in 3 quarters.
  • Cetera Investment Advisers's Hepion Pharmaceuticals position peaked at $15.3K in Q1 2023.
  • 16 funds tracked by Wall St. Rank held Hepion Pharmaceuticals as of Q2 2023.

Based on Cetera Investment Advisers's 13F filing for Q2 2023, filed 10 Aug 2023.